FDA Approves Sanofi, Regeneron Treatment for Chronic Rhinosinusitis with Nasal Polyposis
June 26 2019 - 2:30PM
Dow Jones News
By Michael Dabaie
Sanofi (SNY) and Regeneron Pharmaceuticals Inc. (REGN) said the
U.S. Food and Drug Administration approved Dupixent, or dupilumab,
for use with other medicines to treat chronic rhinosinusitis with
nasal polyposis in adults whose disease isn't controlled.
Sanofi and Regeneron are jointly developing dupilumab under a
global collaboration agreement. CRSwNP is a chronic disease of the
upper airway that obstructs the sinuses and nasal passages.
Dupilumab is the first biologic medicine for adults with
inadequately controlled chronic rhinosinusitis with nasal
polyposis, the companies said. Dupixent significantly reduces nasal
polyp size and improves congestion and loss of smell, while
reducing the need for surgery and systemic corticosteroids, the
companies said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 26, 2019 14:15 ET (18:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Sep 2023 to Sep 2024